This study plans to consecutively enroll the patients with Parkinson's disease (PD) who have confirmed amyloid deposition on amyloid imaging and meet the indications for lecanemab administration. After a thorough explanation of lecanemab administration, patients who consent to the treatment would be enrolled. Patients assinged to the treatment arm would receive standard lecanemab treatment (10mg/kg intravenous infusion every two weeks for 18 months) and standard PD care. Patients who do not consent to the administration of lecanemab would receive stadnard care for PD and be monitored their progress without any further intervention.
Age
50–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Patients diagnosed with Parkinson's disease
2. Amyloid deposition confirmed by FBB PET
3. Mild cognitive impairment or early dementia (CDR 0.5 or 1) on neuropsychological tests
4. Adults aged 50-90 years
You may not be if
1. Cases in which lecanemab administration is contraindicated (based on recommendations from the Korean Dementia Association)
2. Cases in which neuropathologies other than Parkinson's disease or Alzheimer's disease are suspected as the underlying disease
